

Senator HATFIELD. Doctor, are these the documents you are referring to as it related to the involvement here as to whether there was judgment used in letting the company go ahead? Are these the documents you are referring to?

Dr. McCLEERY. Yes, but there are also some letters there which you have not had the opportunity to see, and I just wanted the record to show that I feel you have not had a chance to study the record.

Senator HATFIELD. These will be carefully studied.

Dr. McCLEERY. Thank you.

Senator HATFIELD. They have been studied enough to understand that they are visual aid materials that were not correct in their presentation, that is in their original presentation to you, and that you required certain changes to be made if they were to use them in their detail men's conference to introduce this drug.

Dr. McCLEERY. That is not correct, Senator, but go ahead.

Senator HATFIELD. And that they were to correct or make the corrections according to your requirements, according to Mr. Gordon, our man here, our counsel.

I am saying to you that based on the fact that these were materials which were presented even though they were in corrected form, as you have pasted little things in here, that I feel that there was a judgment, a poor judgment used in making these materials, using these materials that would not be a permanent part of the promotional program.

That is all I am saying, and I would hold the opinion that it was poor judgment by your agency or maybe by you personally, I don't know. But we are not dealing here with facts but a matter of judgment. I am just indicating to you in my judgment, you have obviously indicated to me what your judgment has been.

Dr. McCLEERY. Thank you.

Senator HATFIELD. Are there any other questions now or statements or comments?

Mr. Gordon, do you have anything else?

Mr. GORDON. No.

Senator HATFIELD. We will adjourn until tomorrow morning at 9:30 in the same room.

(The supplemental information submitted by Dr. Minchew follows:)

CHAS. PFIZER & Co., INC.,
New York, N.Y., August 16, 1967.

Re Vibramycin, § 148z.3 and § 148z.4.

ALAN E. SMITH, M.D.,
Acting Deputy Director, Division of Anti-Infective Drugs, Office of New Drugs,
Bureau of Medicine, Food and Drug Administration, Washington, D.C.

DEAR DR. SMITH: We are submitting for your review the proposed Vibramycin visual aid and the Vibramycin Dosage Calculator, which we intend to utilize in the promotion of Vibramycin.

Sincerely yours,

M. G. ADAIR,
FDA Liaison Department.